CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识

2021-04-30 中华肿瘤杂志.2021.43(4):405-413.

CDK4/6抑制剂为激素受体（HR）阳性人表皮生长因子受体２（HER-2）阴性乳腺癌患者的临床管理模式带来革新。全球上市的CDK4/6抑制剂包括哌柏西利、Ribociclib和阿贝西利。对于ＨＲ阳性

中文标题：

发布机构：

发布日期：

2021-04-30

简要介绍：

CDK4/6抑制剂为激素受体（HR）阳性人表皮生长因子受体２（HER-2）阴性乳腺癌患者的临床管理模式带来革新。全球上市的CDK4/6抑制剂包括哌柏西利、Ribociclib和阿贝西利。对于ＨＲ阳性HER-2阴性局部晚期和转移性乳腺癌，CDK4/6抑制剂联合芳香化酶抑制剂或氟维司群一线或二线及以上治疗均可大幅度降低疾病进展或死亡风险，不良反应可控。鉴于CDK4/6 抑制剂联合内分泌治疗在中国的临床应用刚开始起步，国家肿瘤质控中心乳腺癌专家委员会和中国抗癌协会肿瘤药物临床研究专业委员会组织相关领域专家，制定了CDK4/6 抑制剂临床应用专家共识，系统性介绍CDK4/6抑制剂的药理学特征、用药监测以及不良事件管理等，以期加深临床肿瘤医师对CDK4/6 抑制剂药物的认知，推进临床决策的精准性，达到延长患者生存时间和提高生活质量的最终目标。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=8bd411c0021098d8, title=CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识, enTitle=, guiderFrom=中华肿瘤杂志.2021.43(4):405-413., authorId=0, author=, summary=CDK4/6抑制剂为激素受体（HR）阳性人表皮生长因子受体２（HER-2）阴性乳腺癌患者的临床管理模式带来革新。全球上市的CDK4/6抑制剂包括哌柏西利、Ribociclib和阿贝西利。对于ＨＲ阳性, cover=https://img.medsci.cn/2021530/1622304731524_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Fri Apr 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div> <div id="all_content"> <div> <p>CDK4/6抑制剂为激素受体（HR）阳性人表皮生长因子受体２（HER-2）阴性乳腺癌患者的临床管理模式带来革新。全球上市的CDK4/6抑制剂包括哌柏西利、Ribociclib和阿贝西利。对于ＨＲ阳性HER-2阴性局部晚期和转移性乳腺癌，CDK4/6抑制剂联合芳香化酶抑制剂或氟维司群一线或二线及以上治疗均可大幅度降低疾病进展或死亡风险，不良反应可控。鉴于CDK4/6 抑制剂联合内分泌治疗在中国的临床应用刚开始起步，国家肿瘤质控中心乳腺癌专家委员会和中国抗癌协会肿瘤药物临床研究专业委员会组织相关领域专家，制定了CDK4/6 抑制剂临床应用专家共识，系统性介绍CDK4/6抑制剂的药理学特征、用药监测以及不良事件管理等，以期加深临床肿瘤医师对CDK4/6 抑制剂药物的认知，推进临床决策的精准性，达到延长患者生存时间和提高生活质量的最终目标。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=3456, tagName=晚期乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3456, guiderKeyword=晚期乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13640, appHits=100, showAppHits=0, pcHits=855, showPcHits=13540, likes=1, shares=8, comments=10, approvalStatus=1, publishedTime=Sun May 30 00:27:37 CST 2021, publishedTimeString=2021-04-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun May 30 00:12:21 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:38:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=CDK4_6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识.pdf)])

CDK4_6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识.pdf

下载请点击：

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1194178, encodeId=403711941e87c, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Wed Feb 16 22:32:33 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193078, encodeId=8c7311930e809, content=xingkan, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Sun Feb 13 21:15:13 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084446, encodeId=e6e31084446a3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dafa5382371, createdName=ms9000000056725869, createdTime=Sun Dec 26 18:21:13 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015733, encodeId=86bf1015e3382, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2ea24693098, createdName=zhouwenny2013, createdTime=Wed Sep 08 16:43:11 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014830, encodeId=47a7101483079, content=下来看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67535595735, createdName=ms9000001516414209, createdTime=Sun Sep 05 18:58:34 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
2022-02-16 ms3000001297972652

xuexi

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1194178, encodeId=403711941e87c, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Wed Feb 16 22:32:33 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193078, encodeId=8c7311930e809, content=xingkan, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Sun Feb 13 21:15:13 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084446, encodeId=e6e31084446a3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dafa5382371, createdName=ms9000000056725869, createdTime=Sun Dec 26 18:21:13 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015733, encodeId=86bf1015e3382, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2ea24693098, createdName=zhouwenny2013, createdTime=Wed Sep 08 16:43:11 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014830, encodeId=47a7101483079, content=下来看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67535595735, createdName=ms9000001516414209, createdTime=Sun Sep 05 18:58:34 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
2022-02-13 ms3000001297972652

xingkan

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1194178, encodeId=403711941e87c, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Wed Feb 16 22:32:33 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193078, encodeId=8c7311930e809, content=xingkan, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Sun Feb 13 21:15:13 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084446, encodeId=e6e31084446a3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dafa5382371, createdName=ms9000000056725869, createdTime=Sun Dec 26 18:21:13 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015733, encodeId=86bf1015e3382, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2ea24693098, createdName=zhouwenny2013, createdTime=Wed Sep 08 16:43:11 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014830, encodeId=47a7101483079, content=下来看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67535595735, createdName=ms9000001516414209, createdTime=Sun Sep 05 18:58:34 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
2021-12-26 ms9000000056725869

学习

70 0
[GetPortalCommentsPageByObjectIdResponse(id=1194178, encodeId=403711941e87c, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Wed Feb 16 22:32:33 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193078, encodeId=8c7311930e809, content=xingkan, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Sun Feb 13 21:15:13 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084446, encodeId=e6e31084446a3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dafa5382371, createdName=ms9000000056725869, createdTime=Sun Dec 26 18:21:13 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015733, encodeId=86bf1015e3382, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2ea24693098, createdName=zhouwenny2013, createdTime=Wed Sep 08 16:43:11 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014830, encodeId=47a7101483079, content=下来看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67535595735, createdName=ms9000001516414209, createdTime=Sun Sep 05 18:58:34 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
2021-09-08 zhouwenny2013

想看

68 0
[GetPortalCommentsPageByObjectIdResponse(id=1194178, encodeId=403711941e87c, content=xuexi, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Wed Feb 16 22:32:33 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193078, encodeId=8c7311930e809, content=xingkan, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2eb5485299, createdName=ms3000001297972652, createdTime=Sun Feb 13 21:15:13 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084446, encodeId=e6e31084446a3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dafa5382371, createdName=ms9000000056725869, createdTime=Sun Dec 26 18:21:13 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015733, encodeId=86bf1015e3382, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2ea24693098, createdName=zhouwenny2013, createdTime=Wed Sep 08 16:43:11 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014830, encodeId=47a7101483079, content=下来看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67535595735, createdName=ms9000001516414209, createdTime=Sun Sep 05 18:58:34 CST 2021, time=2021-09-05, status=1, ipAttribution=)]
2021-09-05 ms9000001516414209

下来看看

76 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识

相关指南

拓展阅读

科室

工具

服务